Dose response of umeclidinium administered once or twice daily in patients with COPD: a randomised cross-over study

BMC Pulmonary Medicine

Palvi Shah²  Rashmi Mehta⁴  Jean Brooks³  Misba Beerahee¹  Alison Church⁴ 

[1] Clinical Pharmacology Modelling & Simulation, GlaxoSmithKline, Stevenage SG1 2NY, UK;Research & Development, GlaxoSmithKline, Stockley Park, Uxbridge UB11 1BT, UK;Respiratory Medicines Development Centre, GlaxoSmithKline, Stockley Park, Uxbridge UB11 1BT, UK;Respiratory Medicines Development Center, GlaxoSmithKline, Research Triangle Park, NC 27709, USA

关键词: GSK573719;    Umeclidinium (UMEC);    Long-acting muscarinic antagonist (LAMA);    Long-acting bronchodilators;    Chronic obstructive pulmonary disease (COPD);   

Others  :  865457
DOI  :  10.1186/1471-2466-14-2

 received in 2012-11-29, accepted in 2013-12-31,  发布年份 2014

【 摘 要 】

Background

Umeclidinium bromide (UMEC) is an inhaled long-acting muscarinic antagonist in development for chronic obstructive pulmonary disease (COPD).

Methods

This was a multicentre, randomised, double-blind, placebo-controlled, three-way cross-over, incomplete block study to evaluate UMEC 15.6, 31.25, 62.5, and 125 μg administered once daily (QD), and UMEC 15.6 μg and 31.25 μg administered twice daily (BID), over 7 days in patients with COPD. Tiotropium was included as an open-label treatment arm. The primary efficacy endpoint was trough forced expiratory volume in 1 second (FEV₁) on Day 8. Secondary efficacy endpoints included weighted mean FEV₁ over 0–24 hours after morning dosing on Day 7, and serial FEV₁ at each time point over 24 hours after morning dosing on Day 7. Safety and pharmacokinetics were also examined.

Results

One hundred and sixty-three patients (mean age 59.5 years, 52% female) were randomised. Based on the population dose–response model of trough FEV₁ data, the geometric mean potency (ED₅₀) of UMEC was 37 μg (95% confidence interval [CI]: 18, 57) with a predicted maximum intrinsic efficacy (E_max) at trough of 0.185 L (95% CI: 0.153, 0.218) after QD dosing. UMEC 125 μg QD demonstrated the greatest improvements in measure of lung function compared with doses of 62.5 μg and below. UMEC 125 μg QD exhibited more consistent increases in FEV₁ from baseline across serial time points over 24 hours compared with other UMEC doses and tiotropium. Increases in FEV₁ over 0–12 hours were similar to those observed over 12–24 hours after the second dose of UMEC was administered. UMEC was rapidly absorbed following inhaled dosing and eliminated from plasma. Adverse events, generally mild, were highest with UMEC 125 μg QD (18%) compared with placebo (8%), tiotropium (4%) and other UMEC doses (5–12%).

Conclusions

UMEC is a potent QD bronchodilator with geometric mean ED₅₀ of 37 μg. A dose ordering over the range of UMEC 15.6–125 μg QD doses was observed, with UMEC 125 μg showing the greatest improvement in trough FEV₁.

Trial registration

GlaxoSmithKline funded (clinicaltrials.gov NCT01372410; GlaxoSmithKline study number AC4115321).

【 授权许可】

   
2014 Church et al.; licensee BioMed Central Ltd.

【 图 表 】

【 参考文献 】

• [1]Belmonte KE: Cholinergic pathways in the lungs and anticholinergic therapy for chronic obstructive pulmonary disease. Proc Am Thorac Soc 2005, 2:297-304.
• [2]Roffel AF, Elzinga CR, Zaagsma J: Muscarinic M3 receptors mediate contraction of human central and peripheral airway smooth muscle. Pulm Pharmacol 1990, 3:47-51.
• [3]Brusasco V: Reducing cholinergic constriction: the major reversible mechanism in COPD. Eur Respir Rev 2006, 15:32-36.
• [4]GOLD: Global Initiative for Chronic Obstructive Lung Disease. Updated 2013. http://www.goldcopd.org/uploads/users/files/GOLD_Report_2013_Feb20.pdf webcite (Accessed January 3, 2014)
• [5]Cahn A, Tal-Singer R, Pouliquen IJ, Mehta R, Preece A, Hardes K, Crater G, Deans A: Safety, tolerability, pharmacokinetics and pharmacodynamics of single and repeat inhaled doses of umeclidinium in healthy subjects: two randomized studies. Clin Drug Invest 2013, 33:477-488.
• [6]Donohue J, Anzueto A, Brooks J, Crater G, Mehta R, Kalberg C: A Randomized, double-Blind, dose-ranging study of the novel LAMA GSK573719 in patients with COPD. Respir Med 2012, 106:970-979.
• [7]Tal-Singer R, Cahn T, Mehta R, Preece A, Crater G, Kelleher D, Pouliquen IJ: Initial assessment of single and repeat doses of inhaled umeclidinium in patients with chronic obstructive pulmonary disease: Two randomised studies. Eur J Pharmacol 2013, 701:40-48.
• [8]Decramer M, Maltais F, Feldman G, Brooks J, Harris S, Mehta R, Crater G: Bronchodilation of umeclidinium, a new long-acting muscarinic antagonist, in COPD patients. Respir Physiol Neurobiol 2013, 185:393-399.
• [9]Sheiner LB, Hashimoto Y, Beal SL: A simulation study comparing designs for dose ranging. Stat Med 1991, 10:303-331.
• [10]Church A, Beerahee M, Brooks J, Mehta R, Shah P: Umeclidinium (GSK573719) dose response and dosing interval in COPD [abstract]. Eur Respir J 2012, 40(Suppl 56):377s.
• [11]Celli BR, MacNee W: Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J 2004, 23:932-946.
• [12]Hankinson JL, Odencrantz JR, Fedan KB: Spirometric reference values from a sample of the general US population. Am J Resp Crit Care Med 1999, 159:179-187.
• [13]Hankinson JL, Kawut SM, Shahar E, Smith LJ, Hinckley MD, Stukovsky K, Barr RG: Performance of American Thoracic Society-recommended spirometry reference values in a multiethnic sample of adults: the multi-ethnic study of atherosclerosis (MESA) lung study. Chest 2010, 137:138-145.
• [14]WMA Declaration of Helsinki – Ethical Principles for Medical Research Involving Human Subjects. Adopted by the 18th WMA General Assembly, Helsinki, Finland, June 1964 and amended (latest) by the 59th WMA General Assembly, Seoul, Korea, October 2008. http://www.wma.net/en/30publications/10policies/b3/index.html webcite (Accessed January 3, 2014)
• [15]Miller MR, Hankinson J, Brusasco V, Burgos R, Casaburi R: Standardisation for spirometry. Eur Respir J 2005, 26:319-338.
• [16]Vong C, Bergstrand M, Karlson MO: Rapid sample size calculations for a defined likelihood ratio test-based power in mixed effects models [abstract]. Annu Meet Popul Approach Group Eur 2010, 1863:19.
• [17]European Medical Agency guidelines: Guideline on reporting the results of population pharmacokinetic analyses. CHMP/EWP/185990/06. 2007. http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003067.pdf webcite (Accessed January 3, 2014)
• [18]Food and Drug Administration (FDA): Guidance for industry: population pharmacokinetics. U.S. Center for Drug Evaluation and Research; 1999. http://www.fda.gov/downloads/ScienceResearch/SpecialTopics/WomensHealthResearch/UCM133184.pdf webcite (Accessed January 3, 2014)
• [19]Renard D, Looby M, Kramer B, Lawrence D, Morris D, Stanski DR: Characterization of the bronchodilatory dose response to indacaterol in patients with chronic obstructive pulmonary disease using model-based approaches. Respir Res 2011, 12:54. BioMed Central Full Text
• [20]Wang Y, Lee JY, Michele T, Chowdhury BA, Gobburu JV: Limitations of model based dose selection for indacaterol in patients with chronic obstructive pulmonary disease. Int J Clin Pharmacol Ther 2012, 50:622-630.
• [21]Lainé DI, Luttmann MA, Foley JJ, Dehaas CJ, Kotzer CJ, Salmon M, Rumsey WL: The pre-clinical pharmacology of the inhaled muscarinic antagonist GSK573719 predicts once-daily clinical dosing [abstract]. Eur Respir J 2011, 38(Suppl 55):613s.
• [22]Pfizer Inc: Spiriva HandiHaler prescribing information. New York, NY, USA; 2006. http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing+Information/PIs/Spiriva/Spiriva.pdf webcite (Accessed January 3, 2014)